Acta Haematologica
Case Report
Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected ComplicationShimony S.a,b · Reiss Mintz H.c · Shvartser Beryozkin Y.d · Shoham A.e · Raanani P.a,b · Wolach O.a,baInstitute of Hematology, Davidoff Cancer Center, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel
bSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel cDivision of Gastroenterology, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel dDivision of Pathology, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel eRadiology Department, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: February 20, 2019
Accepted: May 14, 2019
Published online: July 10, 2019
Issue release date: January 2020
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 0
ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)
For additional information: https://www.karger.com/AHA
Abstract
Midostaurin is a tyrosine multikinase inhibitor approved for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with mutated Fms-like tyrosine kinase-3. We describe a case report of a 49-year-old AML patient treated with an intensive chemotherapy regimen followed by midostaurin. After achieving complete remission with blood count recovery, he suffered from a serious, rare complication of necrotizing hemorrhagic gastritis with no evidence of infection or malignant infiltration, possibly associated with midostaurin therapy.
© 2019 S. Karger AG, Basel
Related Articles:
References
- Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation [Internet]. N Engl J Med. 2017 Aug;377(5):454–64. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1614359.
- Silen W. The clinical problem of stress ulcers [Internet]. Clin Invest Med. 1987 May;10(3):270–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2887324.
- Marrone GC, Silen W. Pathogenesis, diagnosis and treatment of acute gastric mucosal lesions [Internet]. Clin Gastroenterol. 1984 May;13(2):635–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6430609.
- Pielaciński K, Lech-Marańda E, Warzocha K, Dedecjus M, Prochorec-Sobieszek M, Szczepanik AB. [Necrotizing gastritis in a patient in severe neutropenia]. Pol Merkur Lekarski [Internet]. 2014 Dec;37(222):344–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25715575.
- Takeuchi M, Uno H, Matsuoka H, Maeda K, Marutsuka K, Sumiyoshi A, et al. [Acute necrotizing gastritis associated with adult T-cell leukemia in the course of chemotherapy]. Gan To Kagaku Ryoho. 1995 Feb;22(2):289–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7857107.
-
FDA midosaturin label and safety data. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf%0D.
- Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia [Internet]. N Engl J Med. 2009 Sep;361(13):1249–59. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0904544.
- Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, et al.; UK NCRI AML Study Group. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015 Jun;125(25):3878–85.
- Burnett AK, Russell NH, Hills RK; United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia [Internet]. Blood. 2016 Jul;128(3):449–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27268085.
- King AJ, Eyre T, Rangarajan D, Sampson R, Grech H. Acute isolated transmural neutropenic gastritis. J Clin Oncol. 2012 Jan;30(1):e1–2.
Article / Publication Details
Received: February 20, 2019
Accepted: May 14, 2019
Published online: July 10, 2019
Issue release date: January 2020
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 0
ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)
For additional information: https://www.karger.com/AHA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
